Specialty Pharmacy

Top news of the day from across the health care landscape.

Evidence-based treatment for depression and adherence counseling could boost HIV treatment.

An update of distribution and circulation of HCV genotypes could help reduce disease burden.

The mail-order pharmacy marketplace has significantly changed since the year 2000.

Compared with standard-of-care for patients with inflammatory bowel disease (IBD), a new study found that medication therapy management (MTM) increased adherence more than 30%.

Major pathological tumor regression was experienced by 40% of patients receiving neoadjuvant immunotherapy before resection.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses the relationship between limited distribution networks and specialty pharmacy.

A diagnostic blood test could diagnose patients in early stages of non-alcoholic fatty liver disease.

Top news of the day from across the health care landscape.

HIV compromises the immune system, making patients more susceptible to tuberculosis.

Developing industry connections is crucial for aspiring pharmacists.

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.

Adalimumab also found to be effective in treating non-infectious uveitis.

T cell subset may play a crucial role in the development of diabetes.

Niraparib significantly improved outcomes of platinum-sensitive recurrent ovarian cancer in landmark trial.

Top news of the day from across the health care landscape.

A unique pattern of motion by repair proteins allows them to rapidly scan long DNA and flag repair machinery in condition that can lead to skin cancer.

Coinfection with HIV plus a hepatitis B, C, or both, adds to the risk of non-Hodgkins lymphoma.

Acceptance and utilization of biosimilar drugs still in need of improvement within specialty pharmacy.

Study finds that a food-poisoning bacteria increases the growth of gut bacteria linked to Crohn’s disease.

Adjuvant therapy that improves outcomes for kidney cancer patients may finally be an option.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses how to address the challenge of access to high cost specialty medications.

An award of $347 million has been given to 16 organizations involved with the Hospital Improvement and Innovation Network.

Dupilumab shows benefits for the treatment of asthma and atopic dermatitis.

Ilaris is the first FDA-approved biologic treatment for Tumor Necrosis Factor–Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency and Familial Mediterranean Fever.

Cromolyn sodium associated with reduced liver fibrosis.

Top news of the week in oncology, and cancer drug development.

After keeping her multiple sclerosis diagnosis a secret for more than a decade, Jamie-Lynn Sigler, teamed up with Biogen’s MS campaign.

Results from a phase 3 trial demonstrates that nintedanib improved progression-free survival, but not overall survival in colon cancer patients.

A special technique allowed researchers to detail the structure of an enzyme that causes antibiotic resistance.